Cheney Research » Public Categories

XMRV and CFS Q&A – February 20, 2010

pcheney — Fri, 26 Feb 2010 06:13:52 +0000

Want to be notified on future live web broadcasts? Please sign-up for our free email newsletter.

A retrovirus called XMRV is linked to CFS

pcheney — Fri, 16 Oct 2009 21:53:36 +0000

The finding of antibody or active virus in 95% of CFS and 4% of controls is a result that argues for causality, in my opinion, especially with the associated RNAse-L corruption and NK functional impairment that might predict such an infection. This novel retrovirus could easily shift the redox state just like HIV as has been published in (2001) and (1995) and induce all manner of associated pathogens as seen in CFS. A redox shift could ultimately corrupt the gut ecology and create P450 decoupling based on NADPH depletion observed in CFS and lead to environmental illness as well. Time will tell but I think Dr. Mikovits is right to suspect causality. I also think this virus is infectious with at least ten million Americans infected who appear healthy and perhaps another four million Americans or more with CFS as recently estimated by the CDC (2007). However, disease expression may be more limited causing the illusion that it is not infectious. Furthermore, there may be other diseases that are similar and dissimilar to CFS that are associated with if not caused by XMRV.

Chronic Fatigue Syndrome and Stem Cell Therapy – Latest Research Available at CheneyResearch.com

pcheney — Thu, 08 Oct 2009 11:30:26 +0000

Launching this week, the Cheney Research Web site (www.cheneyresearch.com) is a multimedia medical Web site connecting people who want expert information on Chronic Fatigue Syndrome (CFS) which includes cutting-edge medical concepts and therapies developed at the Cheney Clinic and conveyed in part by extensive use of audio-video format.

About Dr. Cheney

pcheney — Mon, 31 Aug 2009 01:09:33 +0000

Dr. Cheney discusses his educational and experiential background that informs his approach to CFS. This audio-visual presentation of 6 minutes duration by Dr. Cheney explores the background that influences his thinking and philosophy of approach to CFS.

CheneyResearch.com Launches!

pcheney — Thu, 27 Aug 2009 21:07:19 +0000

The Cheney Clinic is proud to announce the launch of its long awaited research-related web site. This site hopes to translate the most up-to-date and clinically useful research conducted at the Cheney Clinic to both patients and clinicians and to increase awareness of the Cheney Clinic's special expertise in cardiac related issues in CFS.

A paucity of autoimmune disease and hypertension in CFS

pcheney — Sun, 03 May 2009 22:16:00 +0000

There is little true autoimmune disease seen in CFS as distinct from autoantibody formation without organ destruction which is more common. Also, there is a significant paucity of hypertension seen in my CFS cohort at less than 1% of all patients with CFS in my practice.

Antibiotics and Dysbiosis

pcheney — Sun, 03 May 2009 22:13:44 +0000

I would agree that some sort of gut dysbiosis strategy is appropriate but more as part of a larger strategy which also addresses redox control points as well as human phenotypic and genotypic corruption. There is as yet, no clear consensus on treating this gut dysbiosis, so I take a pretty conservative approach that follows a 3R strategy (remove, repair and replace) as well as a modified elimination diet and especially fructose elimination.

CFS and the absence of autoimmune disease – ? NO elevation

pcheney — Sat, 02 May 2009 22:17:01 +0000

Very interesting is the relationship of high nitric oxide (NO) to a low incidence of autoimmune disease. In CFS patients, actual autoimmune disease is very rare as is hypertension. There is also the suggestion of high levels of NO in

Antibiotics in CFS

pcheney — Fri, 03 Apr 2009 22:09:50 +0000

To me, CFS is best viewed as a very complex terrain issue and that microbes are simply taking advantage of this fact so that reductionism to drugs or pharmaceuticals directed against single agents or pathways will be a poor therapeutic choice except perhaps early in the illness and in the occasional patient who is much less complex.